8K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
|
Date of report
(Date of earliest event reported):
August 8, 2017
|
|
Commission File
Number:
000-50768
|
|
ACADIA Pharmaceuticals Inc.
|
(Exact name of
registrant as specified in its charter.)
|
|
061376651
|
|
(State or other
jurisdiction of incorporation or organization)
|
(IRS Employer
Identification No.)
|
|
3611 Valley Centre Drive, Suite 300, San Diego, California
92130
|
(Address of
principal executive offices)
(Registrant's
Telephone number)
(Former Name or
Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the Registrant
under any of the following provisions (see General Instruction A.2.
below):
|
[ ]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR
240.12b-2)
|
Emerging growth
company [ ]
|
|
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. [
]
|
Item
2.02 Results
of Operations and Financial Condition.
On August 8, 2017,
ACADIA Pharmaceuticals Inc. issued a press release announcing its
financial results for the second quarter and six months ended June
30, 2017. A copy of this press release is furnished herewith as
Exhibit 99.1. Pursuant to the rules and regulations of the
Securities and Exchange Commission, such exhibit and the
information set forth therein and in this Item 2.02 have been
furnished and shall not be deemed "filed" for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), or otherwise subject to liability under that
section nor shall they be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such filing regardless of any general incorporation
language.
Item
9.01
Financial Statements and Exhibits.
(d) The
following exhibit is furnished herewith:
99.1 Press Release dated August 8,
2017.
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
ACADIA
Pharmaceuticals Inc.
|
Date:
August 8, 2017
|
By:
|
/s/ Glenn F.
Baity
|
|
|
|
Name: Glenn F. Baity
|
|
Title: EVP, General Counsel &
Secretary
|
Exhibit
Index
|
EX-99.1
|
|
Press
Release dated August 8, 2017
|